Sudarshan Pharma Industries Ltd
Incorporated in 2008, Mumbai-based Sudarshan Pharma Industries Limited (SPIL) has a contract manufacturing facility for generic formulations. It is also engaged in import & export activities, and supply of specialty chemicals, API, and Intermediates[1]
- Market Cap ₹ 188 Cr.
- Current Price ₹ 78.0
- High / Low ₹ 91.9 / 62.0
- Stock P/E 22.3
- Book Value ₹ 43.7
- Dividend Yield 0.38 %
- ROCE 15.5 %
- ROE 11.0 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 57.7% CAGR over last 5 years
- Debtor days have improved from 84.5 to 64.5 days.
Cons
- Company has a low return on equity of 13.5% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
|---|---|---|---|---|---|---|---|---|
| 55 | 88 | 139 | 148 | 193 | 357 | 461 | 498 | |
| 55 | 87 | 135 | 143 | 186 | 346 | 446 | 481 | |
| Operating Profit | 1 | 1 | 4 | 5 | 7 | 11 | 15 | 16 |
| OPM % | 1% | 1% | 3% | 3% | 4% | 3% | 3% | 3% |
| 0 | 2 | 1 | 0 | 0 | 0 | 1 | 3 | |
| Interest | 0 | 1 | 2 | 3 | 3 | 3 | 5 | 6 |
| Depreciation | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| Profit before tax | 0 | 1 | 3 | 2 | 4 | 7 | 10 | 11 |
| Tax % | 40% | 24% | 28% | 26% | 25% | 26% | 26% | |
| 0 | 1 | 2 | 1 | 3 | 5 | 7 | 8 | |
| EPS in Rs | 0.74 | 1.57 | 2.46 | 1.34 | 2.80 | 5.39 | 2.93 | 3.50 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 10% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 39% |
| 3 Years: | 46% |
| TTM: | 29% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 58% |
| 3 Years: | 78% |
| TTM: | 36% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 11% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 13% |
| 3 Years: | 14% |
| Last Year: | 11% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 5 | 10 | 10 | 10 | 10 | 24 | 24 |
| Reserves | 1 | 4 | 9 | 10 | 13 | 20 | 77 | 81 |
| 6 | 10 | 14 | 21 | 30 | 31 | 34 | 65 | |
| 11 | 12 | 17 | 18 | 47 | 77 | 97 | 94 | |
| Total Liabilities | 20 | 31 | 50 | 58 | 99 | 138 | 232 | 264 |
| 0 | 0 | 2 | 6 | 6 | 6 | 20 | 21 | |
| CWIP | 0 | 0 | 2 | 0 | 0 | 1 | 0 | 1 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 15 |
| 20 | 31 | 47 | 53 | 93 | 130 | 200 | 227 | |
| Total Assets | 20 | 31 | 50 | 58 | 99 | 138 | 232 | 264 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|---|---|
| -2 | -0 | -1 | 1 | 3 | -4 | -29 | |
| -0 | -0 | -4 | -3 | -1 | -2 | -26 | |
| 2 | -1 | 8 | -0 | -2 | 4 | 66 | |
| Net Cash Flow | 0 | -1 | 3 | -2 | -0 | -1 | 11 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 92 | 71 | 68 | 66 | 114 | 75 | 64 |
| Inventory Days | 23 | 28 | 29 | 46 | 49 | 51 | 63 |
| Days Payable | 75 | 49 | 45 | 40 | 90 | 80 | 78 |
| Cash Conversion Cycle | 40 | 51 | 52 | 72 | 73 | 46 | 50 |
| Working Capital Days | 42 | 52 | 53 | 69 | 75 | 53 | 71 |
| ROCE % | 16% | 20% | 12% | 15% | 19% | 15% |
Documents
Announcements
- Certificate Pursuant To Reg. 40(9) & 40(10) Of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015. 22h
-
Compliances-Compliance Certificate For The Period Ended March, 2024.
20 Apr - Compliance Certificate pursuant to Regulation 7(3) of SEBI (LODR) Regulations 2015.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
15 Apr - Compliance Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 31st March 2024.
-
Announcement under Regulation 30 (LODR)-Change in Management
1 Apr - Sudarshan Pharma Industries Limited hereby intimates the Stock Exchange about the resignation of Ms. Ishita Samani from the position of Company Secretary and Compliance Officer …
-
Announcement under Regulation 30 (LODR)-Cessation
1 Apr - Sudarshan Pharma Industries Limited hereby intimates the Stock Exchange about the resignation of Ms. Ishita Samani from the position of Company Secretary and Compliance Officer …
Business Area
A) Specialty Chemicals, Intermediates & API[1] Co. is involved in Manufacturing, Imports of specialty chemicals & exports, as well as outsourcing & Supply of Specialty chemicals, bulk drugs, and API for domestic and international clients in Pharma, agrochemicals, Paints, resins & various industry.